Auhtors: Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K PMID: 34445197 PMCID: PMC8395185 DOI: 10.3390/ijms22168491 Abstract The term "cachexia" is derived from the Greek words kakos (bad) and hexis (habit). Cachexia is a malnutrition associated with chronic diseases such as cancer, chronic heart failure, chronic renal failure, and autoimmune diseases, and [...]

Auhtors: Advani SM, Advani PG, VonVille HM, Jafri SH PMID: 30482179 PMCID: PMC6260745 DOI: 10.1186/s12885-018-5080-4 Abstract Background: Cachexia is a multisystem syndrome characterized by weight loss, anorexia, loss of muscle mass, systemic inflammation, insulin resistance, and functional decline. Management of cachexia involves addressing multiple underlying biological mechanisms. Previous review on pharmacological management of cancer cachexia [...]

Auhtors: Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH PMID: 29345251 DOI: 10.1038/nrdp.2017.105 Abstract Cancer-associated cachexia is a disorder characterized by loss of body weight with specific losses of skeletal muscle and adipose tissue. Cachexia is driven by a variable combination of reduced food intake and metabolic changes, including elevated energy expenditure, excess [...]

Auhtors: Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC PMID: 26906526 DOI: 10.1016/S1470-2045(15)00558-6 Abstract Background: Patients with advanced cancer frequently experience anorexia and cachexia, which are associated with reduced food intake, altered body composition, and decreased functionality. We assessed anamorelin, a novel ghrelin-receptor agonist, on cachexia in patients with [...]

Auhtors: Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. PMID: 21296615 DOI: 10.1016/S1470-2045(10)70218-7 Abstract To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a [...]